GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRadimed Corp (NAS:IRMD) » Definitions » Financial Strength

IRMD (iRadimed) Financial Strength : 9 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is iRadimed Financial Strength?

iRadimed has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

iRadimed Corp shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

iRadimed has no long-term debt (1). iRadimed's debt to revenue ratio for the quarter that ended in Mar. 2025 was 0.00. As of today, iRadimed's Altman Z-Score is 40.14.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.


Competitive Comparison of iRadimed's Financial Strength

For the Medical Devices subindustry, iRadimed's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iRadimed's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's Financial Strength distribution charts can be found below:

* The bar in red indicates where iRadimed's Financial Strength falls into.


;
;

iRadimed Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

iRadimed's Interest Expense for the months ended in Mar. 2025 was $0.00 Mil. Its Operating Income for the months ended in Mar. 2025 was $5.43 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil.

iRadimed's Interest Coverage for the quarter that ended in Mar. 2025 is

iRadimed had no long-term debt (1).

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. iRadimed Corp has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

iRadimed's Debt to Revenue Ratio for the quarter that ended in Mar. 2025 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2025 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.059 + 0) / 78.044
=0.00

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

iRadimed has a Z-score of 40.14, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 40.14 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iRadimed  (NAS:IRMD) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

iRadimed has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.


iRadimed Financial Strength Related Terms

Thank you for viewing the detailed overview of iRadimed's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


iRadimed Business Description

Traded in Other Exchanges
Address
1025 Willa Springs Drive, Winter Springs, FL, USA, 32708
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Executives
John Glenn officer: Chief Financial Officer 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Anthony Vuoto director
Monty K Allen director
Roger E. Susi director, 10 percent owner, officer: CEO, President, Chairman C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
James B Hawkins director C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Hilda Frederique Scharen-guivel director 440 PALM ISLAND SE, CLEARWATER BEACH FL 33767
Christopher K. Scott officer: CHIEF FINANCIAL OFFICER & SECR C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Brent Johnson officer: Exec. VP. Sales & Marketing 4900 HOPYARD RD, SUITE 210, PLEASITAN CA 94588
Steven M. Nardi officer: VP MANUFACTURING C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Louis S. Waldman officer: CONTROLLER C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Leslie L Mcdonnell director, officer: Chief Exec Officer & Director 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Francis X. Casey officer: VP OF REG AND QUAL ASSURANCE C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
John K Mccreery officer: Chief Operating Officer IRADIMED CORP, 1025 WILLA SPRINGS BLVD, WINTER SPRINGS FL 32708
Jonathan Kennedy director INTERSIL CORPORATION, 1001 MURPHY RANCH ROAD, MILPITAS CA 95035
Serge Novovich director C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708